More trial data backs Merck's cervical cancer shot (Reuters)
Date : 2008 02 07 Category : Health
Reuters - New data from a combined analysis of
four Phase II/III studies involving more than 20,000 women
confirm the effectiveness of Merck & Co Inc's cervical cancer
vaccine Gardasil, researchers said on Thursday.